
1. malar j. 2018 mar 12;17(1):108. doi: 10.1186/s12936-018-2252-2.

the d113n mutation ring e3 ubiquitin protein ligase gene associated
with ex vivo susceptibility common anti-malarial drugs african plasmodium
falciparum isolates.

gendrot m(1)(2), foguim ft(1)(2), robert mg(1)(2), amalvict r(1)(2)(3), mosnier
j(1)(2)(3), benoit n(1)(2)(3), madamet m(1)(2)(3), pradines b(4)(5)(6); french
national reference centre imported malaria study group.

collaborators: augis v, basset d, bastien p, benoit-vical f, berry a, brouqui p, 
cividin m, delaunay p, delhaes l, drancourt m, gaillard t, genin a, garnotel e,
javelle e, l'ollivier c, leveque m, malvy d, marty p, mechain m, ménard g, millet
p, minodier p, mottard a, parola p, piarroux r, pomares-estran c, receveur m-,
robin a, sappa e, savini h, simon f, sterkers y, surcouf c, varlet e, wolff a.

author information: 
(1)unité parasitologie et entomologie, département des maladies infectieuses,
institut de recherche biomédicale des armées, institut hospitalo-universitaire
(ihu) méditerranée infection, 19-21 boulevard jean moulin, 13005, marseille,
france.
(2)aix marseille univ, ird, ap-hm, ssa, vitrome, ihu-méditerranée infection,
marseille, france.
(3)centre national de référence du paludisme, institut hospitalo-universitaire
(ihu) méditerranée infection, marseille, france.
(4)unité parasitologie et entomologie, département des maladies infectieuses,
institut de recherche biomédicale des armées, institut hospitalo-universitaire
(ihu) méditerranée infection, 19-21 boulevard jean moulin, 13005, marseille,
france. bruno.pradines@gmail.com.
(5)aix marseille univ, ird, ap-hm, ssa, vitrome, ihu-méditerranée infection,
marseille, france. bruno.pradines@gmail.com.
(6)centre national de référence du paludisme, institut hospitalo-universitaire
(ihu) méditerranée infection, marseille, france. bruno.pradines@gmail.com.

background: plasmodium falciparum resistance artemisinin-based combination
therapy emerged spread southeast asia. areas artemisinin
resistance emerging, efficacy combination based partner
drugs. context, identification novel markers resistance is
essential monitor emergence spread resistance partner
drugs. ubiquitylation pathway could possible target anti-malarial
compounds might involved resistance. polymorphisms e3
ubiquitin-protein ligase (pf3d7_0627300) gene could associated decreased 
in vitro susceptibility anti-malarial drugs.
methods: plasmodium falciparum isolates collected patients hospitalized
in france imported malaria malaria-endemic country january 2015 
to december 2016 and, particularly, african french-speaking countries. 
in total, 215 isolates successfully sequenced e3 ubiquitin-protein
ligase gene assessed ex vivo susceptibility anti-malarial drugs.
results: d113n mutation ring e3 ubiquitin-protein ligase gene was
present 147 215 samples (68.4%). ic50 values ten
anti-malarial drugs significantly different wild-type and
mutant parasites (p values 0.225 0.933). significant
difference terms percentage parasites decreased susceptibility 
between d113 wild-type 133n mutated p. falciparum strains (p values
between 0.541 1).
conclusion: present data confirmed absence association between
polymorphisms ring e3 ubiquitin-protein ligase gene ex vivo
susceptibility common anti-malarial drugs african p. falciparum isolates.

doi: 10.1186/s12936-018-2252-2 
pmcid: pmc5848522
pmid: 29530046  [indexed medline]

